1887

Abstract

This study investigated the clinician response to the extended-spectrum -lactamase (ESBL) confirmation report generated by an automated detection system, MicroScan Walkaway. The study compared two cohorts (pre- and post-automated detection) of patients with an ESBL-producing or species non-urinary infection over the period October 2001–December 2006. Acceptance of the report, as defined by the initiation of carbapenem therapy, was observed in 69.2 % of the post-automated detection cohort (=78) versus 20 % in the pre-automated detection period (=15) ( ≤0.001). The utilization of a carbapenem increased progressively over the course of the study. Moreover, the time to initiation of carbapenem therapy was reduced from 15.7±4.9 to 0.1±2.0 days ( ≤0.001) after implementation of this automated detection system. Overall, clinicians responded positively to the ESBL automated detection report, as gauged by the increased utilization of a carbapenem and the earlier initiation of appropriate therapy; however, reductions in length of stay and mortality were not observed in this infected population.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.2008/000430-0
2008-09-01
2019-10-14
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/9/1147.html?itemId=/content/journal/jmm/10.1099/jmm.0.2008/000430-0&mimeType=html&fmt=ahah

References

  1. Bonomo, R. A. ( 2000; ). Multiple antibiotic-resistant bacteria in long-term care facilities: an emerging problem in the practice of infectious disease. Clin Infect Dis 31, 1414–1422.[CrossRef]
    [Google Scholar]
  2. Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. ( 1987; ). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40, 373–383.[CrossRef]
    [Google Scholar]
  3. CLSI ( 2006; ). Performance Standards for Antimicrobial Susceptibility Testing, 16th Information Supplement, M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute.
  4. Crnich, C. J., Safdar, N., Robinson, J. & Zimmerman, D. ( 2007; ). Longitudinal trends in antibiotic resistance in US nursing homes, 2000–2004. Infect Control Hosp Epidemiol 28, 1006–1008.[CrossRef]
    [Google Scholar]
  5. Dandekar, P. K., Tetreault, J., Quinn, J., Nightingale, C. H. & Nicolau, D. P. ( 2004; ). Prevalence of extended spectrum β-lactamase producing Escherichia coli and Klebsiella isolates in a large community teaching hospital in Connecticut. Diagn Microbiol Infect Dis 49, 37–39.[CrossRef]
    [Google Scholar]
  6. Gavin, P. J., Bolden, J. R., Peterson, L. R. & Thomson, R. B., Jr ( 2006; ). Does identification of an extended-spectrum β-lactamase-producing organism by the microbiology laboratory influence patient management? Infect Dis Clin Pract 14, 81–83.[CrossRef]
    [Google Scholar]
  7. Jones, R. N. ( 2001; ). Resistance patterns among nosocomial pathogens. Trends over the past few years. Chest 119, 397S–404S.[CrossRef]
    [Google Scholar]
  8. Kang, C. I., Kim, S. H., Park, W. B., Lee, K. D., Kim, H. B., Kim, E. C., Oh, M. D. & Choe, K. W. ( 2004; ). Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcomes, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48, 4574–4581.[CrossRef]
    [Google Scholar]
  9. Knaus, W. A., Draper, E. A., Wagner, D. P. & Zimmerman, J. E. ( 1985; ). APACHE II: a severity of disease classification system. Crit Care Med 13, 818–829.[CrossRef]
    [Google Scholar]
  10. Lautenbach, E., Patel, J. B., Bilker, W. B., Edelstein, P. H. & Fishman, N. O. ( 2001; ). Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 32, 1162–1171.[CrossRef]
    [Google Scholar]
  11. Lee, S. Y., Kotapati, S., Kuti, J. L., Nightingale, C. H. & Nicolau, D. P. ( 2006; ). Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 27, 1226–1232.[CrossRef]
    [Google Scholar]
  12. Paterson, D. L. & Bonomo, R. A. ( 2005; ). Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 18, 657–686.[CrossRef]
    [Google Scholar]
  13. Paterson, D. L., Ko, W. C., Von Gottberg, A., Mohapatra, S., Casellas, J. M., Goossens, H., Mulazimoglu, L., Trenholme, G., Klugman, K. P. & other authors ( 2004; ). Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis 39, 31–37.[CrossRef]
    [Google Scholar]
  14. Wiener, J., Quinn, J. P., Bradford, P. A., Goering, R. V., Nathan, C., Bush, K. & Weinstein, R. A. ( 1999; ). Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 281, 517–523.[CrossRef]
    [Google Scholar]
  15. Wong-Beringer, A., Hindler, J., Loeloff, M., Queenan, A. M., Lee, N., Pegues, D. A., Quinn, J. P. & Bush, K. ( 2002; ). Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 34, 135–146.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.2008/000430-0
Loading
/content/journal/jmm/10.1099/jmm.0.2008/000430-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error